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Abstract: Hypoxia-inducible factor 1-alpha (HIF1a) and its regulator von Hippel–Lindau protein (VHL)
play an important role in tumour ischemia. Currently, drugs that target HIF1a are being developed
to treat malignancies. Although HIF1a is known to be expressed in uveal melanoma (UM), it is as
yet unknown which factors, such as tumour size or genetics, determine its expression. Therefore,
we aimed to determine which tumour characteristics relate to HIF1a expression in UM. Data from
64 patients who were enucleated for UM were analysed. Messenger RNA (mRNA) expression was
determined with the Illumina HT-12 v4 chip. In 54 cases, the status of chromosomes 3 and 8q, and
BRCA1-associated protein 1 (BAP1) protein expression (immunohistochemistry) were determined.
Findings were corroborated using data of 80 patients from the Cancer Genome Atlas (TCGA) study.
A significantly increased expression of HIF1a, and a decreased expression of VHL were associated
with monosomy 3/loss of BAP1 expression. The relationship between BAP1 loss and HIF1a expression
was independent of chromosome 3. The largest basal diameter and tumour thickness showed no
relationship with HIF1a. HIF1a expression related to an increased presence of infiltrating T cells and
macrophages. From this study, we conclude that HIF1a is strongly related to tumour genetics in UM,
especially to loss of BAP1 expression, and less to tumour size. Tumour ischemia is furthermore related
to the presence of an inflammatory phenotype.
Keywords: uveal melanoma; ischemia; HIF1a; oncology; infiltrate; BAP1; chromosomes; gene
expression
1. Introduction
Uveal melanoma (UM) is the most common intraocular primary malignancy in Caucasian adults,
with an incidence of 5.1 per million in the United States (US) [1]. Smaller and medium-sized UMs
are often treated with brachytherapy or external radiotherapy (such as electron beam or proton beam
irradiation), while larger lesions may require enucleation. Up to 50% of UM patients will develop
metastases [2] and, unfortunately, no effective treatment for metastatic disease currently exists. Various
prognostic parameters were identified in UM, with a poor prognosis associated with large tumours
and ciliary body involvement [3]. Genetic predictors for metastatic tumour behaviour are monosomy 3,
gain of chromosome 8q, loss of BRCA1-associated protein 1 (BAP1) expression and a Class II gene
expression profile [4]. Several new biomarkers were studied, and an increased expression of markers
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including PRAME [5], ADAM10 [6] and ABCB5 [7] were found to be associated with a greater risk for
metastasis in UM.
Recent developments in oncology highlighted the importance of ischemia in the behaviour of solid
tumours. Ischemia describes a shortage of oxygen supply from the blood. An important mediator is
hypoxia inducible factor 1-alpha (HIF1a), which is increased in ischemic conditions, and activates various
pro-angiogenic mechanisms (such as the production of vascular endothelial growth factor (VEGF)) to
ultimately regain oxygen [8]. This link between HIF1a and increased vascular growth was established
in many malignancies [8–10]. The main opponent of HIF1a is the von Hippel–Lindau protein (VHL),
which ubiquitinates and degrades HIF1a [11]. VHL is mainly known for its role in the VHL syndrome, a
disease caused by a mutation in the VHL gene on the short arm of chromosome 3, and this syndrome
is associated with the development of various malignant diseases, including hemangioblastoma of
the retina and of the central nervous system, and with tumours as renal cell carcinoma (RCC) and
pheochromocytoma [12].
In several solid organ malignancies, a high HIF1a expression is related to a poor clinical outcome [8].
This includes colorectal cancer [13] and melanoma of the skin [10]. Mouriaux showed that, in UM,
a high HIF1a expression is associated with cell proliferation (MIB-1 expression), expression of the
vascular marker CD31 (also known as “platelet and endothelial cell adhesion molecule 1” (PECAM1))
and the cytokine VEGF [14]. Expanding UMs need to attract new blood vessels for their oxygenation,
and one would expect that tumour size would, therefore, be a strong determinant of HIF1a expression.
While cell culture of UM under hypoxic conditions increased the expression of HIF1a [15], another study
reported that HIF1a expression could also be demonstrated in UM cell lines grown under normoxic
conditions, implicating that more mechanisms than hypoxia alone are involved in regulating HIF1a [16].
Interestingly, Mouriaux implicated an oxygen-independent mechanism for HIF1a expression, since it
was spread throughout the whole tumour and not restricted to hypoxic areas [14]. It is currently not
known which tumour factors, such as size, genetics, or the presence of an immune infiltrate, relate to
ischemia in UM.
Highly interesting is the development of new drugs that can target HIF1a, as this may provide a
new treatment for metastatic UM [17]. More knowledge on the function of HIF1a in UM is needed,
however, before this treatment can be fully exploited. We hypothesized that either tumour size or
genetic determinants will regulate the expression of HIF1a and set out to investigate which tumour
characteristics determine the expression levels of this molecule and its regulator VHL, using a set of
patients from the Leiden University Medical Center (LUMC, Leiden, the Netherlands), and subsequently
corroborated our findings using data from the Cancer Genome Atlas (TCGA).
2. Results
2.1. Expression of VHL, but Not HIF1a, Is Related to Clinical Characteristics
Information on tumour mRNA expression was available for 64 UMs. The mean age of the patients
was 60.6 years. The median tumour largest basal diameter (LBD) was 13.0 mm, and the median tumour
prominence 8.0 mm. The tumour-node-metastasis (TNM) categories of the tumours were T1 in six (9%),
T2 in 25 (39%), T3 in 31 (48%), and T4 in two cases (3%). The median follow-up time was 62.0 months
(min 2, max 205). In 27 patients (42%), metastases developed, followed by melanoma-related death
(Table 1). Nine patients died from other causes.
The median HIF1a messenger RNA (mRNA) expression level in the 64 tumours was 7.21 (range:
6.87–7.95). Expression levels were not associated with gender (p = 0.32), age (p = 0.11), ciliary body
involvement (p= 0.40), LBD (p= 0.49), tumour prominence (p= 0.89), TNM category (p = 0.76), or tumour
pigmentation (p = 0.42). Increased expression was not significantly related to an epithelioid/mixed cell
type (p = 0.095) and the presence or absence of metastasis (p = 0.091) (Table 1). However, a high HIF1a
expression was related to worse survival in a Kaplan–Meier analysis (Figure 1).
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Table 1. Clinical characteristics of the study group (Leiden data, n = 64), and messenger RNA (mRNA)
expression levels of hypoxia-inducible factor 1-alpha (HIF1a) and von Hippel–Lindau (VHL).
Total HIF1a VHL
Categorical Cases (%) Median p-Value Median p-Value
Gender
Male 33 (52) 7.20 0.32 # 8.04 0.039 #
Female 31 (48) 7.25 7.70
Side
Right eye (OD) 30 (47) 7.17 0.57 # 7.84 0.84 #
Left eye (OS) 34 (53) 7.24 7.82
TNM cat. (8th)
T1 6 (9) 7.14 0.76 * 7.96 0.32 *
T2 25 (39) 7.23 8.01
T3 31 (48) 7.22 7.76
T4 2 (3) 7.07 7.75
Tumour Pigmentation
Light 43 (67) 7.15 0.42 # 8.04 0.29 #
Dark 20 (31) 7.27 7.75
Cell Type
Spindle 22 (34) 7.14 0.095 # 8.08 0.23 #
Mixed + epithelioid 42 (66) 7.24 7.78
Ciliary Body Involvement
No 40 (63) 7.17 0.40 # 8.03 0.022 #
Yes 23 (36) 7.24 7.70
Metastasis
No 27 (42) 7.10 0.091 # 8.18 <0.001 #
Yes 37 (58) 7.24 7.71
Melanoma-Related Death
No 27 (42) 7.10 0.091 # 8.18 <0.001 #
Yes 37 (58) 7.24 7.71
Correlation Correlation
Numerical Total Spearman p-Value Spearman p-Value
Age—Median 61.6 0.201 0.11 −0.331 0.008
LBD—Median 13.0 −0.088 0.49 −0.274 0.028
Prominence—Median 8.0 0.018 0.89 −0.024 0.85
The p-values were calculated with the following: # Mann–Whitney U test, * Jonckheere test for trends. Abbreviations:
TNM, tumour node metastasis; LBD, largest basal diameter; Cat, category.
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Figure 1. Patient survival in relation to messenger RNA (mRNA) gene expression of (a) hypoxia-
inducible factor 1-alpha (HIF1a) and (b) von Hippel–Lindau (VHL). Groups (high vs. low) were based 
on the median mRNA gene expression values (n = 64). 
Figure 1. Patient survival in relation to messenger RNA (mRNA) gene expression of (a) hypoxia-inducible
factor 1-alpha (HIF1a) and (b) von Hippel–Lindau (VHL). Groups (high vs. low) were based on the
median mRNA gene expression values (n = 64).
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The median VHL mRNA expression level in the 64 tumours was 7.82 (range: 6.96–8.60).
A decreased expression was observed with female gender (p = 0.039), older age (p = 0.008), ciliary body
involvement (p = 0.022), larger LBD (p = 0.028), the occurrence of metastasis (p < 0.001), and worse
melanoma-related survival (p < 0.001, Figure 1), but was not associated with TNM category (p = 0.32),
tumour prominence (p = 0.85), pigmentation (p = 0.29), or cell type (p = 0.23) (Table 1).
2.2. HIF1a and VHL Expression Are Related to the Presence of T Cells (CD3, CD8) and Macrophages (CD68)
Hypoxia is known to activate various cell types of the immune system, resulting in, e.g., an
increased presence of pro-angiogenic macrophages [18]. We wondered how ischemia related to the
inflammatory microenvironment in UM, and studied the relationship between HIF1a mRNA gene
expression and the presence of various immunological cell types. The expression of HIF1a was related
to an increased expression of lymphocyte markers CD3 (p < 0.001), CD4 (p = 0.027), CD8 (p < 0.001),
and the macrophage marker CD68 (p < 0.001). The expression of VHL was inversely related to infiltrate
(CD3: p = 0.040, CD8: p = 0.012, and CD68: p = 0.024) (Table 2).
Table 2. Messenger RNA (mRNA) expression of ischemic and vascular markers, and immune infiltrate.
The correlation between hypoxia-inducible factor 1-alpha (HIF1a), von Hippel–Lindau (VHL) expression
and other genes is shown (based on the n = 64 lesions with data on HIF1a/VHL expression from the
Leiden data).
HIF1a VHL
mRNA Correlation p-Value Correlation p-Value
Ischemic Markers
HIF1A NA NA −0.380 0.002 *
VHL −0.380 0.002 * NA NA
Vascular Markers
VEGFA 0.052 0.682 −0.003 0.984
VEGFB −0.333 0.007 * 0.337 0.006 *
VEGFC −0.049 0.702 −0.147 0.245
PECAM1 0.381 0.002 * −0.381 0.002 *
CD34 0.121 0.342 −0.085 0.502
VWF 0.321 0.010 * 0.057 0.653
Immune Infiltrate
CD3D 0.428 <0.001 * −0.257 0.040 *
CD4 0.276 0.027 * −0.167 0.188
CD8A 0.452 <0.001 * −0.314 0.012 *
CD68 0.549 <0.001 * −0.282 0.024 *
Other
BAP1 −0.330 0.008 * 0.554 <0.001 *
The p-values were calculated with Spearman correlation; * indicates significant p-values. NA, not applicable.
2.3. HIF1a and VHL Expression Are Related to the Expression of Several Angiogenesis-Related Genes
To identify the pathways that are involved in ischemia in UM, we compared the expression of
HIF1a and VHL to other genes with relevance to angiogenesis and hypoxia. HIF1a levels showed an
inverse correlation with VHL (p = 0.002) and VEGF-B (p = 0.007), and a significantly positive correlation
with PECAM1 (p = 0.002) and Von Willebrand Factor (VWF) (p = 0.01). While this may point to an
increased vascular growth with higher HIF1a expression, no significant correlation was observed
between HIF1a and expression of VEGF-A (p = 0.68) or endothelial marker CD34 (p = 0.34). VHL was
related to a significantly increased expression of VEGF-B (p = 0.006), and a significantly decreased
expression of HIF1a (p = 0.002) and PECAM1 (p = 0.002) (Table 2).
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2.4. Tumour Ischemia Is Related to Chromosome 3 and BAP1, but Not to Chromosome 8q
Tumour genetics influence inflammation, as tumours with an extra copy of chromosome 8q are
known to have more macrophages, while loss of one chromosome 3 is associated with a complete
inflammatory phenotype, containing a mixture of T cells and macrophages [3,19]. We wondered if these
genetic aberrations also influence HIF1a levels. We tested this hypothesis in 54 of the 64 enucleated
UMs of which chromosome data and information on the expression of the prognostically important
BAP1 protein were available. Data on mRNA expression of several genes, including HIF1a and VHL,
were also reported in a previous study [20].
Tumours with monosomy 3 (M3) (n = 34) had a higher expression of HIF1a (p = 0.001) and a lower
expression of VHL (p < 0.001) compared to tumours with disomy 3 (D3) (n = 20) (Table 3). Similarly,
BAP1-negative tumours (n = 30) had a higher expression of HIF1a (p < 0.001) and a lower expression
of VHL (p = 0.003) compared to BAP1-positive tumours (n = 24) (Table 3). This was corroborated using
the TCGA data (Table S2).
Table 3. Analysis of hypoxia-inducible factor 1-alpha (HIF1a) and von Hippel–Lindau (VHL) mRNA
expression in relation to chromosome status and BAP1 (based on the n = 54 lesions with data on
HIF1a/VHL and chromosome status from the Leiden data).
Total HIF1a VHL
CATEGORICAL Cases (%) Median p-Value Median p-Value
All patients
Chromosome 3
D3 20 (37) 7.02 0.001 * 8.23 <0.001 *
M3 34 (63) 7.24 7.69
Chromosome 8q
Normal 13 (24) 7.01 0.003 * 8.22 0.001 *
Gain 41 (76) 7.24 7.74
BAP1 IHC
Negative 30 (56) 7.28 <0.001 * 7.71 0.003 *
Positive 24 (54) 7.02 8.17
Sub-group analysis
Within D3 Lesions
D3/BAP1− 3 7.30 0.028 * 8.23 0.921
D3/BAP1+ 17 7.01 8.23
Within M3 Lesions
M3/BAP1− 27 7.25 0.015 * 7.70 0.647
M3/BAP1+ 7 7.10 7.56
Within D3/BAP1+ Lesions
D3/BAP1+/n8q 9 6.98 0.200 8.22 1.000
D3/BAP1+/8qgain 8 7.07 8.32
The p-values were calculated with the Mann–Whitney U test; * indicates significant p-values. Abbreviations: BAP1+,
BAP1-positive; BAP1−, BAP1-negative; n8q, normal chromosome 8q; 8qgain, gain of chromosome 8q; D3, disomy 3;
M3, monosomy 3; IHC, immunohistochemistry.
To investigate the role of BAP1 independently of chromosome 3 status, we analysed the association
between BAP1 and HIF1a/VHL within the D3 and M3 tumours separately. Within the set of D3 tumours,
BAP1-negative tumours (n = 3) had a higher expression of HIF1a compared to BAP1-positive tumours
(n = 17, p = 0.028). Similarly, within the set of M3 tumours, BAP1-negative tumours (n = 27) had a
higher expression of HIF1a compared to BAP1-positive tumours (n = 7) (p = 0.015) (Table 3). This
implies that HIF1a has especially a strong correlation with BAP1 loss, in addition to its correlation with
chromosome 3 status (Figure 2a). Interestingly, VHL expression was not related to BAP1 within either
the D3 or M3 group (p = 0.92 and p = 0.65, respectively) (Figure 2b). As the VHL gene is located on
3p25, it may not come as a surprise that VHL expression relates more strongly to M3 than to BAP1 loss.
In the TCGA data, it was confirmed that BAP1 loss relates to increased HIF1a expression within M3
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tumours. No relation could be established within D3 patients, as only one case with BAP1 loss and D3
was present (Table S2).Cancers 2019, 11, x 6 of 13 
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Figure 2. Expression of hypoxia-inducible factor 1-alpha (HIF1a) and von Hippel–Lindau (VHL) mRNA
in relation to chromosome status and BRCA1-associated protein 1 (BAP1) loss. (a) HIF1a expression is
significantly increased with BAP1 loss in both disomy 3 (D3) and monosomy 3 (M3) tumours. (b) VHL
expression is strongly dependent on chromosome 3 status, but is not dependent on BAP1 status within
D3 or M3 tumours. (c) HIF1a expression is not increased with the early eve t of 8q gain, but is i creased
with the later event of BAP1 loss (n = 52, excluding two cases of BAP1-n8q). (d) A with HIF1a, VHL
expression is not dependent on early events as 8q gain, but is decreased with later events as loss of
BAP1 (n = 52, excluding two cases of BAP1-n8q). (e) Adjusted for status of chromosome 3, there is no
significant relationship between largest basal diameter (LBD) and expression of HIF1a. (f) Adjusted
for status of chromosome 3, there is no significant relationship between LBD and expression of VHL.
(Abbreviations: BAP1+, BAP1-positive; BAP1−, BAP1-negative; n8q, normal chromosome 8q; 8qgain,
gain of chromosome 8q; LBD, largest basal diameter; D3, disomy 3; M3, monosomy 3).
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While loss of BAP1 (or M3) is considered a late event during UM tumour evolution, gain of 8q is
considered an early event [21,22]. When analysing all cases, gain of chromosome 8q was associated
with an increased expression of HIF1a (p = 0.003) and a decreased expression of VHL (p = 0.001);
however, 8q gain itself was associated with BAP1 loss/M3. Within the group of D3 lesions (and also
within lesions with both D3 and BAP1 expression), 8q gain was no longer associated with either HIF1a
or VHL (all p > 0.10) (Table 3) (Figure 2c,d). In the TCGA data, 8q gain was similarly not associated
with HIF1a and VHL within D3 or M3 lesions (Table S2).
2.5. Ischemia Is More Related to Tumour Genetics Than to Tumour Size
We demonstrated that both HIF1a and VHL are strongly related to tumour genetics, and wondered
how this related to tumour size. HIF1a expression was not related to LBD or tumour prominence in a
univariate regression analysis (p = 0.21 and p = 0.67, respectively). In a multivariate model with the
addition of either chromosome 3 or BAP1 status, tumour size also did not relate significantly to HIF1a
expression (Table 4, Figure 2e). This was equally seen in the TCGA group (Table S3). From this, we
conclude that HIF1a relates more strongly to tumour genetics than to tumour size.
Table 4. Univariate and multivariate regression analysis on hypoxia-inducible factor 1-alpha (HIF1a)
and von Hippel–Lindau (VHL) mRNA expression (based on the n = 54 lesions with data on HIF1a/VHL
and chromosome status from the Leiden data).
HIF1a VHL
Variables B (95% CI) p-Value B (95% CI) p-Value
Univariate Regression
Chr. 3 (M3 vs. D3) 0.17 (0.03; 0.32) 0.019 * −0.51 (−0.65; −0.37) <0.001 *
BAP1 (BAP1− vs. BAP1+) −0.26 (−0.39; −0.14) <0.001 * 0.31 (0.13; 0.48) 0.001 *
LBD (per mm increase) −0.01 (−0.03; 0.01) 0.208 −0.03 (−0.05; −0.002) 0.034 *
Multivariate Regression
Model 1
Chr. 3 0.01 (−0.16; 0.17) 0.952 −0.51 (−0.70; −0.33) <0.001 *
BAP1 −0.26 (−0.43; −0.10) 0.002 * −0.01 (−0.18; 0.17) 0.957
Model 2
LBD −0.02 (−0.03; 0.002) 0.086 −0.03 (−0.05; −0.002) 0.034 *
BAP1 −0.27 (−0.40; −0.15) <0.001 * 0.30 (0.13; 0.47) 0.001 *
Model 3
LBD −0.02 (−0.04; 0.00) 0.055 −0.01 (−0.03; 0.006) 0.173
Chr. 3 0.20 (0.06; 0.35) 0.006 * −0.49 (−0.63; −0.34) <0.001 *
Univariate Regression
Within D3 (n = 20)
LBD −0.05 (−0.10; 0.004) 0.067 −0.04 (−0.08; −0.004) 0.033 *
Within M3 (n = 34)
LBD −0.01 (−0.03; 0.008) 0.230 −0.006 (−0.03; 0.02) 0.605
* indicates significant p-values. Abbreviations: CI, confidence interval; Chr. 3, chromosome 3; LBD, largest basal
diameter; D3, disomy 3; M3, monosomy 3.
The expression of VHL related negatively to tumour LBD (univariate regression analysis, p = 0.034),
with larger tumours having lower VHL. In a multivariate model which included LBD and BAP1
staining, the relationship between LBD and VHL remained significant (p = 0.034). In a multivariate
model which included LBD and chromosome 3, the significance of LBD was lost (p = 0.17, Figure 2f),
indicating that VHL expression depends highly on chromosome 3 status. Within D3 lesions (n = 20),
a significant relationship was found between LBD and lower VHL (univariate regression analysis,
p = 0.033), indicating that tumour size may have an initial role in VHL expression, but is overshadowed
by the effect of M3 as soon as this event occurs. In the TCGA data, neither LBD nor tumour prominence
were related to VHL expression (also not within D3 or M3 cases), stressing the importance of tumour
genetics over tumour size for VHL levels as well (Table S3).
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3. Discussion
We evaluated how the expression of HIF1a and VHL relates to clinical and genetic factors in
UM and established that genetics, but not tumour size, are strongly associated with the level of these
markers. M3 and BAP1 loss, but not 8q gain, were related to HIF1a expression, while expression of
VHL was mainly determined by the status of chromosome 3. Tumour size only had a role in VHL
expression in D3 lesions.
The general theory states that angiogenesis is the result of intra-tumoural hypoxia, which leads
to the activation of HIF1a, and the subsequent activation of pro-angiogenic factors such as VEGF.
There are several hypoxia-independent mechanisms that lead to the activation of HIF1a, however,
as was reported in (cutaneous) melanoma for the phosphoinositide 3-kinsase (PI3K) signalling or
presence of reactive oxygen species (ROS) and increased nuclear factor kappa-B (NF-κB) activity [23].
Mouriaux found that HIF1a expression was spread throughout UM tissue, and not limited to hypoxic
areas, which implicated a hypoxia-independent activation [14]. Our study indicates that loss of BAP1
expression is highly correlated with HIF1a expression in UM, while M3 is highly correlated with loss of
VHL expression. These findings help to understand our recent study that demonstrated that tumour
angiogenesis is strongly related to the genetic make-up in UM, with BAP1 loss and M3 being related to
an increased microvascular density [20].
The gene coding for VHL is located on chromosome 3p25. From renal cell carcinoma (RCC),
it is known that chromosome 3 loss leads to VHL inactivation, and a subsequent increase in HIF1a.
This HIF1a increase leads to the highly vascular nature of RCC [24]. In our study, the location of
the VHL gene also explains the strong correlation between chromosome 3 status and expression of
VHL. The location of the VHL gene also explains why we detected a correlation with several clinical
characteristics, such as the link between a decreased VHL expression and ciliary body involvement,
which is known to relate to M3 in UM [3].
We identified that BAP1 loss is strongly associated with the expression of HIF1a, even after
adjustment for tumour size or chromosome 3 status. As the gene coding for HIF1a is located on 14q23,
it is logical that it is less related to the genetic status of chromosome 3 than VHL. The association
between BAP1 loss and HIF1a expression was corroborated in the TCGA data with multivariate
regression including BAP1 and chromosome 3, LBD, or tumour prominence (Table S3).
While many reports stress the importance of BAP1 loss for events in UM development and
behaviour, the mechanisms are not fully understood. Even so, it is unknown how BAP1 loss can cause
an increase of HIF1a. The situation is similar in RCC—a tumour that depends highly on VHL—where
BAP1 loss was associated with an increased risk of RCC-related death, although the mechanism is also
not yet understood [25]. As BAP1 indirectly suppresses NF-κB via transcription elongation factor A
like 7 (TCEAL7) (in human oesophageal squamous cell carcinoma) [26], it can be hypothesized that
BAP1 loss leads to an upregulation of HIF1a via the NF-κB cascade. Indeed, it was found that BAP1
loss is associated with an increased NF-κB expression in UM [27]. This might also explain the presence
of an inflammatory mixed infiltrate, which we describe as being associated with HIF1a expression.
An explanation for the absent relationship between chromosome 8q status and ischemia in our
study may be that gain of 8q is an early event (occurring in smaller, non-hypoxic cases of UM) and that
8q gain is not directly related to other strong activators of HIF1a. Gain of 8q may be too early in the
angiogenic switch to have a noticeable effect on ischemia. Gezgin et al. demonstrated that gain of 8q is
related to the influx of pro-angiogenic macrophages in UM [28]; however, it may be that this precedes
the development of marked ischemia.
We established a relationship between HIF1a expression and the presence of macrophages and
lymphocytes in UM. Tumour-associated macrophages are studied more often in cutaneous melanoma,
as it is clear that they have a pro-angiogenic function, helping the tumour to overcome a hypoxic
environment [18]. Moreover, this is of clinical relevance as the presence of M2 macrophages was
related to a worse survival in UM [29]. Earlier, it was noticed that hypoxia leads to the polarization
of mainly M2 type macrophages [30], which is the predominant type in UM [29]. Another study
Cancers 2019, 11, 1004 9 of 12
found that UM stimulated migration of macrophages independent of growth under normoxic or
hypoxic conditions; this points towards a non-oxygenation-dependent generation of the inflammatory
environment [31], and is in line with our findings that the genetic status, especially with regard to
BAP1, is important in determining HIF1a, as well as the macrophage influx, possibly by the earlier
mentioned NF-κB pathway.
The relationship between hypoxia and T cells in tumours is far less understood. Doedens et al.
found that HIF1a promoted the function of CD8+ T cells [32]. In our study, we confirm that higher HIF1a
expression is related to the presence of CD8+ T cells in UM. An interesting homeostatic mechanism may
be suggested, however, as macrophages (activated by HIF1a) may suppress the function of antitumour
CD8+ T cells [33,34]. The balance between pro-metastatic macrophages and antitumour CD8+ cells
may, therefore, be difficult to predict in ischemic UM.
A strength of our study was that data of two independent datasets were available. A limitation
was the small number of patients in some sub groups of our analysis, hampering statistical comparison.
Another limitation was that all tumour samples were obtained from enucleated eyes, including mainly
larger tumours with a limited variation in tumour size. A third limitation was that we studied mRNA
expression and not protein levels. In the TCGA, BAP1 loss was based on the median mRNA expression
value, and not on immunohistochemistry (IHC), as was possible with the Leiden data.
Future studies could investigate if blocking the HIF1a pathway has true clinical benefit in UM.
We demonstrated that expression of HIF1a and VHL as indicators of ischemia are clearly related to
tumour genetics and inflammation in UM, and less to tumour size. This information helps us better
understand the difference between metastasizing and non-metastasizing UM. It should be investigated
if the HIF1a pathway is involved in the behaviour of UM metastases, to identify if targeting HIF1a is a
potential treatment for already disseminated UM.
4. Materials and Methods
4.1. Patient Selection
Tumour samples were obtained from 64 patients who were treated for a UM by primary enucleation
at the Leiden University Medical Center (LUMC, Leiden, the Netherlands) between 1999 and 2008.
Clinical data were retrieved from patient medical charts, and complemented with survival data from the
Dutch national cancer registry (Registratie Applicatie Nederlandse Kankerregistratie (RANK)). The study
was approved by the Biobank Committee of the LUMC (19.061.CBO/uveamelanoomlab-2019-2).
The tenets of the Declaration of Helsinki were followed.
4.2. Histopathology
Tumour material was snap-frozen using 2-methyl butane. Remaining tumour material was fixed
in 4% neutral-buffered formalin for 48 h and embedded in paraffin. Haematoxylin/eosin-stained 4-µm
sections were reviewed by an ocular pathologist for confirmation of the diagnosis and evaluated for
histologic parameters (Largest basal diameter (LBD), prominence, cell type, pigmentation). The eighth
edition of the American Joint Committee on Cancer (AJCC) staging manual was used for tumour
classification [35].
4.3. Gene Expression
Messenger RNA was isolated from frozen tumour material for gene expression analysis using the
RNeasy Mini Kit (Qiagen, Venlo, the Netherlands). The Illumina HT-12 v4 chip was used to determine
gene expression levels (Illumina, San Diego, CA, USA). Hypoxia- and angiogenesis-related factors
were selected based on the literature regarding angiogenesis in UM (Table S4). Probes for CD3, CD8,
and CD68 were previously validated [28].
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4.4. Chromosome Status and BAP1 Status
The QIAmp DNA Mini Kit was used to isolate DNA for single-nucleotide polymorphism (SNP)
analysis (Qiagen, Venlo, The Netherlands). Chromosome 3 status was determined with SNP analysis
performed with the Affymetrix 250K_NSP chip and the Affymetrix Cytoscan HD chip (Affymetrix,
Santa Clara, CA, USA) [22]. Status of chromosome 8q was identified with dPCR. A threshold of >2.1
was defined as having gain of 8q [22]. BAP1 status was assessed with immunohistochemistry (IHC) as
previously described [36], using a mouse monoclonal antibody raised against amino acids 430–729 of
human BAP1 (clone sc-28383, 1:50 dilution, Santa Cruz Biotechnology, Dallas, TX, USA). Tumours
were scored by an experienced ocular pathologist (R.M.V.) on nuclear staining, and categorized as
BAP1-positive or BAP1-negative.
4.5. TCGA
Analyses were corroborated using mRNA expression data from 80 UM patients from the TCGA
project (http://cancergenome.nih.gov/) [37], with a median follow-up time of 26.0 months (Table S1).
In this set, BAP1 expression was provided as mRNA expression levels, and dichotomized at the median
into BAP1-positive and BAP1-negative cases [28].
4.6. Statistical Analysis
Analyses were performed using SPSS version 23. Data were analysed with the Mann–Whitney
U test due to non-parametrical distribution (numerical parameters, two groups) or the Jonckheere
test for trends (numerical parameters, more than two groups). Correlations were assessed using the
Spearman’s rho. Linear regression was performed for univariate and multivariate analyses. Survival
was analysed using Kaplan–Meier graphs with log-rank tests. The threshold between “high” and
“low” expression of HIF1a and VHL was based on the median expression values. Two-sided tests were
reported, and p-values <0.05 were considered statistically significant.
5. Conclusions
Ischemia—as determined by HIF1a expression—is strongly related to tumour genetics in UM.
Expression of HIF1a is increased in tumours with monosomy 3 and BAP1 loss, but not with gain of
chromosome 8q. Moreover, the role of tumour genetics in expression of HIF1a is more pronounced
than the role of tumour size. These findings help to understand the process of angiogenesis in UM,
which is a known risk factor for metastasis development. Also, this implies that the genetic make-up
of UM should be considered while investigating the efficacy of HIF1a-targeting drugs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/7/1004/s1:
Table S1: Clinical characteristics of the TCGA study group, Table S2: Analysis of HIF1a and VHL mRNA expression
in relation to chromosome status and BAP1 (TCGA data), Table S3: Univariate and multivariate regression analysis
on HIF1a and VHL expression (TCGA data), Table S4: Overview of hypoxia- and angiogenesis-related genes.
Author Contributions: Conceptualization, N.J.B. and M.J.J.; formal analysis, N.J.B., A.P.A.W., and M.J.J.; investigation,
A.P.A.W., G.G., M.M., G.P.M.L., W.G.M.K., M.V., P.A.v.d.V., and R.M.V.; methodology, N.J.B. and M.J.J.; resources,
A.P.A.W., G.G., M.M., G.P.M.L., W.G.M.K., M.V., P.A.v.d.V., and R.M.V.; supervision, M.J.J.; writing—original draft,
N.J.B. and M.J.J.; writing—review and editing, all.
Funding: This project was supported by Algemene Nederlandse Vereniging Ter Voorkoming van Blindheid (ANVVB),
Stichting Blinden Penning, Landelijke Stichting voor Blinden en Slechtzienden (LSBS), Novartis Foundation, Stichting
Nederlands Oogheelkundig Onderzoek (SNOO), Rotterdamse Stichting Blindenbelangen, MD/PhD program grant
of the LUMC, and the European Commission Horizon 2020 programme UM Cure (project number: 667787).
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Singh, A.D.; Turell, M.E.; Topham, A.K. Uveal melanoma: Trends in incidence, treatment, and survival.
Ophthalmology 2011, 118, 1881–1885. [CrossRef] [PubMed]
Cancers 2019, 11, 1004 11 of 12
2. Damato, B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye
2012, 26, 1157–1172. [CrossRef] [PubMed]
3. Maat, W.; Ly, L.V.; Jordanova, E.S.; de Wolff-Rouendaal, D.; Schalij-Delfos, N.E.; Jager, M.J. Monosomy of
chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest. Ophthalmol. Vis. Sci.
2008, 49, 505–510. [CrossRef] [PubMed]
4. Dogrusoz, M.; Jager, M.J.; Damato, B. Uveal Melanoma Treatment and Prognostication. Asia Pac. J. Ophthalmol.
2017, 6, 186–196.
5. Field, M.G.; Decatur, C.L.; Kurtenbach, S.; Gezgin, G.; van der Velden, P.A.; Jager, M.J.; Kozak, K.N.;
Harbour, J.W. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin. Cancer Res.
2016, 22, 1234–1242. [CrossRef] [PubMed]
6. Caltabiano, R.; Puzzo, L.; Barresi, V.; Ieni, A.; Loreto, C.; Musumeci, G.; Castrogiovanni, P.; Ragusa, M.;
Foti, P.; Russo, A.; et al. ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of
metastasis. Pathol. Res. Pract. 2016, 212, 980–987. [CrossRef] [PubMed]
7. Broggi, G.; Musumeci, G.; Puzzo, L.; Russo, A.; Reibaldi, M.; Ragusa, M.; Longo, A.; Caltabiano, R.
Immunohistochemical expression of ABCB5 as a potential prognostic factor in uveal melanoma. Appl. Sci.
2019, 9, 1316. [CrossRef]
8. Rankin, E.B.; Giaccia, A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15,
678–685. [CrossRef] [PubMed]
9. Musumeci, G.; Castorina, A.; Magro, G.; Cardile, V.; Castorina, S.; Ribatti, D. Enhanced expression of
CD31/platelet endothelial cell adhesion molecule 1 (PECAM1) correlates with hypoxia inducible factor-1
alpha (HIF-1alpha) in human glioblastoma multiforme. Exp. Cell Res. 2015, 339, 407–416. [CrossRef]
10. Giatromanolaki, A.; Sivridis, E.; Kouskoukis, C.; Gatter, K.C.; Harris, A.L.; Koukourakis, M.I. Hypoxia-inducible
factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis
in nodular malignant melanomas of the skin. Melanoma Res. 2003, 13, 493–501. [CrossRef]
11. Pugh, C.W.; Ratcliffe, P.J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1)
degradation, and cancer pathogenesis. Semin. Cancer Biol. 2003, 13, 83–89. [CrossRef]
12. Aronow, M.E.; Wiley, H.E.; Gaudric, A.; Krivosic, V.; Gorin, M.B.; Shields, C.L.; Shields, J.A.; Jonasch, E.W.;
Singh, A.D.; Chew, E.Y. Von Hippel-Lindau disease: Update on pathogenesis and systemic aspects. Retina
2019. [CrossRef] [PubMed]
13. Baba, Y.; Nosho, K.; Shima, K.; Irahara, N.; Chan, A.T.; Meyerhardt, J.A.; Chung, D.C.; Giovannucci, E.L.;
Fuchs, C.S.; Ogino, S. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal
cancers. Am. J. Pathol. 2010, 176, 2292–2301. [CrossRef] [PubMed]
14. Mouriaux, F.; Sanschagrin, F.; Diorio, C.; Landreville, S.; Comoz, F.; Petit, E.; Bernaudin, M.; Rousseau, A.P.;
Bergeron, D.; Morcos, M. Increased HIF-1alpha expression correlates with cell proliferation and vascular
markers CD31 and VEGF-A in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2014, 55, 1277–1283. [CrossRef]
[PubMed]
15. El Filali, M.; Missotten, G.S.; Maat, W.; Ly, L.V.; Luyten, G.P.; van der Velden, P.A.; Jager, M.J. Regulation of
VEGF-A in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2010, 51, 2329–2337. [CrossRef]
16. Asnaghi, L.; Lin, M.H.; Lim, K.S.; Lim, K.J.; Tripathy, A.; Wendeborn, M.; Merbs, S.L.; Handa, J.T.; Sodhi, A.;
Bar, E.E.; et al. Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation.
PLoS ONE 2014, 9, e105372. [CrossRef] [PubMed]
17. Dong, L.; You, S.; Zhang, Q.; Osuka, S.; Devi, N.S.; Kaluz, S.; Ferguson, J.H.; Yang, H.; Chen, G.; Wang, B.;
et al. Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces
primary tumor growth and metastasis of uveal melanoma. Clin. Cancer Res. 2019, 25, 2206–2218. [CrossRef]
18. Huber, R.; Meier, B.; Otsuka, A.; Fenini, G.; Satoh, T.; Gehrke, S.; Widmer, D.; Levesque, M.P.; Mangana, J.;
Kerl, K.; et al. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1
and M2-like macrophages. Sci. Rep. 2016, 6, 29914. [CrossRef]
19. Bronkhorst, I.H.; Vu, T.H.; Jordanova, E.S.; Luyten, G.P.; Burg, S.H.; Jager, M.J. Different subsets of
tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma.
Invest. Ophthalmol. Vis. Sci. 2012, 53, 5370–5378. [CrossRef]
20. Brouwer, N.J.; Gezgin, G.; Wierenga, A.P.A.; Bronkhorst, I.H.; Marinkovic, M.; Luyten, G.P.; Versluis, M.;
Kroes, W.G.; Van der Velden, P.A.; Verdijk, R.M.; et al. Tumour angiogenesis in uveal melanoma is related to
genetic evolution. Cancers 2019, 11, 979. [CrossRef]
Cancers 2019, 11, 1004 12 of 12
21. Singh, N.; Singh, A.D.; Hide, W. Inferring an evolutionary tree of uveal melanoma from genomic copy
number aberrations. Invest. Ophthalmol. Vis. Sci. 2015, 56, 6801–6809. [CrossRef] [PubMed]
22. Versluis, M.; de Lange, M.J.; van Pelt, S.I.; Ruivenkamp, C.A.; Kroes, W.G.; Cao, J.; Jager, M.J.; Luyten, G.P.;
van der Velden, P.A. Digital PCR validates 8q dosage as prognostic tool in uveal melanoma. PLoS ONE 2015,
10, e0116371. [CrossRef] [PubMed]
23. Meierjohann, S. Hypoxia-independent drivers of melanoma angiogenesis. Front. Oncol. 2015, 5, 102. [CrossRef]
[PubMed]
24. Hsieh, J.J.; Le, V.H.; Oyama, T.; Ricketts, C.J.; Ho, T.H.; Cheng, E.H. Chromosome 3p loss-orchestrated VHL,
HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J. Clin. Oncol 2018, 36, 3533–3539. [CrossRef]
[PubMed]
25. Su, D.; Singer, E.A.; Srinivasan, R. Molecular pathways in renal cell carcinoma: Recent advances in genetics
and molecular biology. Curr. Opin. Oncol. 2015, 27, 217–223. [CrossRef] [PubMed]
26. Mori, T.; Sumii, M.; Fujishima, F.; Ueno, K.; Emi, M.; Nagasaki, M.; Ishioka, C.; Chiba, N. Somatic alteration
and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma. Cancer Sci. 2015,
106, 1118–1129. [CrossRef]
27. Souri, Z.; Wierenga, A.P.A.; Van Weeghel, C.; Van der Velden, P.A.; Kroes, W.G.; Luyten, G.P.; Van der
Burg, S.H.; Jochemsen, A.G.; Jager, M.J. NFkB pathway and HLA Class I expression in uveal melanoma.
Cancers 2019. (under review).
28. Gezgin, G.; Dogrusöz, M.; van Essen, T.H.; Kroes, W.G.M.; Luyten, G.P.M.; van der Velden, P.A.; Walter, V.;
Verdijk, R.M.; van Hall, T.; van der Burg, S.H.; et al. Genetic evolution of uveal melanoma guides the development
of an inflammatory microenvironment. Cancer Immunol. Immunother. 2017, 66, 903–912. [CrossRef]
29. Bronkhorst, I.H.; Ly, L.V.; Jordanova, E.S.; Vrolijk, J.; Versluis, M.; Luyten, G.P.; Jager, M.J. Detection of
M2-macrophages in uveal melanoma and relation with survival. Invest. Ophthalmol. Vis. Sci. 2011, 52, 643–650.
[CrossRef]
30. Campillo, N.; Falcones, B.; Otero, J.; Colina, R.; Gozal, D.; Navajas, D.; Farre, R.; Almendros, I. Differential
oxygenation in tumor microenvironment modulates macrophage and cancer cell crosstalk: Novel experimental
setting and proof of concept. Front. Oncol. 2019, 9, 43. [CrossRef]
31. Bronkhorst, I.H.; Jehs, T.M.; Dijkgraaf, E.M.; Luyten, G.P.; van der Velden, P.A.; van der Burg, S.H.; Jager, M.J.
Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma. JAMA Ophthalmol.
2014, 132, 614–621. [CrossRef] [PubMed]
32. Doedens, A.L.; Phan, A.T.; Stradner, M.H.; Fujimoto, J.K.; Nguyen, J.V.; Yang, E.; Johnson, R.S.; Goldrath, A.W.
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat. Immunol.
2013, 14, 1173–1182. [CrossRef] [PubMed]
33. Ly, L.V.; Baghat, A.; Versluis, M.; Jordanova, E.S.; Luyten, G.P.; van Rooijen, N.; van Hall, T.;
van der Velden, P.A.; Jager, M.J. In aged mice, outgrowth of intraocular melanoma depends on proangiogenic
M2-type macrophages. J. Immunol. 2010, 185, 3481–3488. [CrossRef] [PubMed]
34. Doedens, A.L.; Stockmann, C.; Rubinstein, M.P.; Liao, D.; Zhang, N.; DeNardo, D.G.; Coussens, L.M.;
Karin, M.; Goldrath, A.W.; Johnson, R.S. Macrophage expression of hypoxia-inducible factor-1 alpha
suppresses T-cell function and promotes tumor progression. Cancer Res. 2010, 70, 7465–7475. [CrossRef]
[PubMed]
35. Kivela, T.; Simpson, E.R.; Grossniklaus, H.E.; Jager, M.J.; Singh, A.D.; Caminal, J.M.; Pavlick, A.C.; Kujala, E.;
Coupland, S.E.; Finger, P.T. Uveal Melanoma. In AJCC Cancer Staging Manual, 8th ed.; Amin, M.B., Edge, S.,
Greene, F., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R.,
Sullivan, D.C., et al., Eds.; Springer Publishing Company: New York, NY, USA, 2017; pp. 805–817.
36. Koopmans, A.E.; Verdijk, R.M.; Brouwer, R.W.; van den Bosch, T.P.; van den Berg, M.M.; Vaarwater, J.;
Kockx, C.E.; Paridaens, D.; Naus, N.C.; Nellist, M.; et al. Clinical significance of immunohistochemistry for
detection of BAP1 mutations in uveal melanoma. Mod. Pathol. 2014, 27, 1321–1330. [CrossRef] [PubMed]
37. Robertson, A.G.; Shih, J.; Yau, C.; Gibb, E.A.; Oba, J.; Mungall, K.L.; Hess, J.M.; Uzunangelov, V.; Walter, V.;
Danilova, L.; et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma.
Cancer Cell 2017, 32, 204–220. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
